Maura Camozzi

999 total citations
15 papers, 840 citations indexed

About

Maura Camozzi is a scholar working on Molecular Biology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maura Camozzi has authored 15 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Immunology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maura Camozzi's work include Biomarkers in Disease Mechanisms (5 papers), Angiogenesis and VEGF in Cancer (5 papers) and Advanced Breast Cancer Therapies (3 papers). Maura Camozzi is often cited by papers focused on Biomarkers in Disease Mechanisms (5 papers), Angiogenesis and VEGF in Cancer (5 papers) and Advanced Breast Cancer Therapies (3 papers). Maura Camozzi collaborates with scholars based in Italy, United States and Spain. Maura Camozzi's co-authors include Marco Presta, Marco Rusnati, Giovanni Salvatori, Barbara Bottazzi, Alberto Mantovani, Emanuela Moroni, Daria Leali, Giuseppe Peri, Alberto Amadori and Stefano Indraccolo and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Maura Camozzi

15 papers receiving 825 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maura Camozzi Italy 11 451 370 107 105 100 15 840
Guenther Eissner Germany 8 210 0.5× 424 1.1× 107 1.0× 48 0.5× 34 0.3× 14 586
Dan Hauzenberger Sweden 18 225 0.5× 178 0.5× 98 0.9× 116 1.1× 116 1.2× 37 772
Adam Asch United States 8 371 0.8× 171 0.5× 48 0.4× 54 0.5× 42 0.4× 27 689
Raquel Ruz Reyes Spain 11 184 0.4× 366 1.0× 49 0.5× 136 1.3× 50 0.5× 18 634
Fang Dong China 15 259 0.6× 340 0.9× 44 0.4× 187 1.8× 71 0.7× 62 778
Alessandra Metelli United States 11 304 0.7× 380 1.0× 103 1.0× 84 0.8× 71 0.7× 11 893
Shashi Singh Pawar United States 10 241 0.5× 309 0.8× 34 0.3× 53 0.5× 70 0.7× 19 650
Srinivas Mamidi Germany 14 485 1.1× 391 1.1× 51 0.5× 47 0.4× 50 0.5× 21 868
Joachim Taminau Belgium 10 326 0.7× 326 0.9× 30 0.3× 90 0.9× 113 1.1× 14 660
Lorena Alba‐Castellón Spain 16 181 0.4× 426 1.2× 67 0.6× 90 0.9× 52 0.5× 30 703

Countries citing papers authored by Maura Camozzi

Since Specialization
Citations

This map shows the geographic impact of Maura Camozzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maura Camozzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maura Camozzi more than expected).

Fields of papers citing papers by Maura Camozzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maura Camozzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maura Camozzi. The network helps show where Maura Camozzi may publish in the future.

Co-authorship network of co-authors of Maura Camozzi

This figure shows the co-authorship network connecting the top 25 collaborators of Maura Camozzi. A scholar is included among the top collaborators of Maura Camozzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maura Camozzi. Maura Camozzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Joensuu, Heikki, Jean‐Yves Blay, Alessandro Comandone, et al.. (2017). Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer. 117(9). 1278–1285. 33 indexed citations
2.
3.
4.
Jérusalem, Guy, Gabriella Mariani, Miguel Martín, et al.. (2015). Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04). Open Repository and Bibliography (University of Liège). 75(9). 1 indexed citations
5.
Joensuu, Heikki, Jean‐Yves Blay, Alessandro Comandone, et al.. (2014). Phase 2 Trial to Evaluate the Efficacy and Safety of Dovitinib in Patients (Pts) with Gastrointestinal Stromal Tumor (Gist) Refractory and/or Intolerant to Imatinib (Im). Annals of Oncology. 25. v1–v1. 2 indexed citations
6.
Alessi, Patrizia, et al.. (2009). Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. European Cytokine Network. 20(4). 225–234. 59 indexed citations
7.
Andrés, Germán, Daria Leali, Stefania Mitola, et al.. (2008). A pro‐inflammatory signature mediates FGF2‐induced angiogenesis. Journal of Cellular and Molecular Medicine. 13(8b). 2083–2108. 58 indexed citations
8.
Presta, Marco, Maura Camozzi, Giovanni Salvatori, & Marco Rusnati. (2007). Role of the soluble pattern recognition receptor PTX3 in vascular biology. Journal of Cellular and Molecular Medicine. 11(4). 723–738. 152 indexed citations
9.
Camozzi, Maura, Marco Rusnati, Antonella Bugatti, et al.. (2006). Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3. Journal of Biological Chemistry. 281(32). 22605–22613. 100 indexed citations
10.
Presta, Marco, Daria Leali, Helena Stabile, et al.. (2005). Heparin Derivatives and Semisynthetic Biotechnological Heparins as Angiogenesis Inhibitors. 2(1). 371–391. 1 indexed citations
11.
Camozzi, Maura, Serena Zacchigna, Marco Rusnati, et al.. (2005). Pentraxin 3 Inhibits Fibroblast Growth Factor 2–Dependent Activation of Smooth Muscle Cells In Vitro and Neointima Formation In Vivo. Arteriosclerosis Thrombosis and Vascular Biology. 25(9). 1837–1842. 85 indexed citations
12.
Alfano, Massimo, et al.. (2004). Inhibition of intra‐ and extra‐cellular Tat function and HIV expression by pertussis toxin B‐oligomer. European Journal of Immunology. 34(2). 530–536. 12 indexed citations
13.
Rusnati, Marco, Maura Camozzi, Emanuela Moroni, et al.. (2004). Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood. 104(1). 92–99. 164 indexed citations
14.
Presta, Marco, Pasqua Oreste, G Zoppetti, et al.. (2004). Antiangiogenic Activity of Semisynthetic Biotechnological Heparins. Arteriosclerosis Thrombosis and Vascular Biology. 25(1). 71–76. 33 indexed citations
15.
Presta, Marco, Daria Leali, Helena Stabile, et al.. (2003). Heparin Derivatives as Angiogenesis Inhibitors. Current Pharmaceutical Design. 9(7). 553–566. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guenther Eissner Breakdown of academic impact, for papers by Dan Hauzenberger Breakdown of academic impact, for papers by Adam Asch Breakdown of academic impact, for papers by Raquel Ruz Reyes Breakdown of academic impact, for papers by Fang Dong Breakdown of academic impact, for papers by Alessandra Metelli Breakdown of academic impact, for papers by Shashi Singh Pawar Breakdown of academic impact, for papers by Srinivas Mamidi Breakdown of academic impact, for papers by Joachim Taminau Breakdown of academic impact, for papers by Lorena Alba‐Castellón
Rankless by CCL
2026